Shingles Vaccine and Dementia: What the Evidence Shows
Key takeaways · 10 min read
- In Wales, people born just after a 1933 cutoff could get the shingles vaccine and those born just before could not. Over seven years, vaccination cut new dementia diagnoses by 3.5 percentage points, a 20% relative reduction.
- Similar natural experiments in Australia and Canada found smaller effects of eligibility, about 2 percentage points; the Welsh effect was concentrated in women.
- Studies of the newer Shingrix vaccine are observational. One found a hazard ratio of 0.49 against the unvaccinated but 0.73 against people who had a different vaccine, a sign of how much healthy-vaccinee bias can inflate results.
- A 2026 critique argued that the effects implied by the natural experiments are internally inconsistent, with two of them above 100%. No randomised trial has yet tested dementia as an outcome.
In this article
- What shingles does on its own
- The birthday that split Wales
- Australia, Canada and the deaths
- Newer vaccine, bigger databases
- Why the numbers may not hold
- Who is offered the vaccine
- Eligibility today: the CDC and UK schedules side by side
- What the evidence supports
- Questions people ask
- The short version
- Sources
On 1 September 2013, Wales started offering the shingles vaccine to people aged 79. Anyone born on or after 2 September 1933 became eligible at some point; anyone born before that date never did. One week either side of the line, uptake differed sharply: 0.01% of people one week too old were vaccinated, against 47.2% of those one week younger.
People born a few days apart are alike in almost every way that matters for dementia, so the arbitrary date turned a public-health programme into something close to a randomised trial: one group could get the vaccine and the other could not. In April 2025, a team led by Pascal Geldsetzer at Stanford reported in Nature that the eligible group went on to have fewer dementia diagnoses.
The finding has since been repeated in other countries, extended to deaths and challenged in print. The sections below cover what the Welsh study and its successors found, what the larger observational studies of the newer vaccine add, why some researchers think the numbers do not hang together, and what the vaccine is proven to do regardless.

What shingles does on its own
Shingles is the chickenpox virus, varicella zoster, waking up decades after a childhood infection. The CDC estimates that about one in three people in the United States will get it during their lifetime, around a million cases a year, and that the risk rises sharply after the age of 50. Postherpetic neuralgia, nerve pain that can last for months after the rash heals, follows in 10% to 18% of cases.
Two vaccines have been used. Zostavax, a live weakened virus, cut shingles by 51.3% in a trial of 38,546 older adults published in 2005, but its protection waned: one large analysis estimated effectiveness at 68% in the first year and 47% in the second. Shingrix, a non-live recombinant vaccine with an adjuvant called AS01, did far better in its trials and has replaced Zostavax in the United States since 2020 and in the UK since 2023.
How well the vaccines prevent shingles itself
Efficacy against shingles in the main randomised trials.
Sources: Lal H et al., NEJM (2015), doi:10.1056/NEJMoa1501184; Cunningham AL et al., NEJM (2016), doi:10.1056/NEJMoa1603800; Oxman MN et al., NEJM (2005), doi:10.1056/NEJMoa051016.
The protection against shingles is not in doubt; everything else in this article concerns a possible extra benefit.
The birthday that split Wales
Using primary-care records for 282,541 older adults, the Welsh study compared people on either side of the line, a design called regression discontinuity, on the grounds that uptake jumped at the cutoff but nothing else should. Over seven years, eligibility for the live vaccine was followed by fewer new diagnoses of dementia. Translated into the effect of actually being vaccinated, new dementia diagnoses fell by 3.5 percentage points (95% CI 0.6 to 7.1), a relative reduction of 20.0%.
The cutoff in Wales
Vaccine uptake one week either side of the eligibility date, and the estimated effect of vaccination over seven years.
Vaccinated: 0.01%
Never eligible
Vaccinated: 47.2%
Effect of vaccination on new dementia diagnoses: −3.5 points (−20%)
Source: Eyting M, Xie M, Michalik F et al., Nature 641:438–446 (2025), doi:10.1038/s41586-025-08800-x. Natural experiment using routine records; the outcome is a recorded diagnosis.
The obvious objection is that something else might change at the same birth date, and the authors checked the ten leading causes of illness and death in Wales and found no jump at the cutoff in any of them. Shingles diagnoses did fall, by 37.2% in relative terms, as they should if the vaccine was doing its known job. The effect on dementia was stronger in women; in an earlier version of the paper, estimates for men were close to zero, although the confidence interval did not rule out a meaningful benefit.
The outcome is a dementia diagnosis in a GP record, and much dementia goes undiagnosed. The people studied were about 79 or 80 when the programme began, follow-up lasted at most about eight years, and the vaccine was Zostavax, which is no longer used in most programmes.
Australia, Canada and the deaths
Australia began its own programme in November 2016 for people aged 70 to 79, with a birth-date cutoff of 2 November 1936. A study of records from 65 general practices, published in JAMA in April 2025, found that eligibility reduced new dementia diagnoses by 1.8 percentage points (95% CI 0.4 to 3.3) over 7.4 years. Uptake was 30.2% among the eligible and 6.5% among the ineligible. The authors did not convert this into an effect per vaccinated person, because vaccination is under-recorded in Australian GP data, and they noted that dementia was heavily under-diagnosed: 1.4% of over-65s in their data had a diagnosis, against an estimated true prevalence of 8.4%.
A Canadian study in The Lancet Neurology in 2026 used Ontario’s birth-date cutoffs and reported about 2 percentage points fewer dementia diagnoses over 5.5 years. A further Welsh analysis in Cell, in December 2025, looked further along the disease course. Vaccination was associated with fewer diagnoses of mild cognitive impairment, and among people already diagnosed with dementia, with fewer deaths from dementia. Deaths from other causes did not change, which is what would be expected if the effect were real rather than a general marker of health; the reduction in dementia deaths was again clear in women and not in men.
Three natural experiments
Change in new dementia diagnoses associated with a birth-date cutoff for the live shingles vaccine. Wales reports the effect of vaccination; Australia and Canada report the effect of eligibility, which is smaller because not everyone eligible was vaccinated.
| Country | Follow-up | Measure | Change in diagnoses |
|---|---|---|---|
| Wales | 7 years | Effect of vaccination | −3.5 points (−20%) |
| Australia | 7.4 years | Effect of eligibility | −1.8 points |
| Canada (Ontario) | 5.5 years | Effect of eligibility | about −2.0 points |
Sources: Eyting et al., Nature (2025); Pomirchy M et al., JAMA (2025), doi:10.1001/jama.2025.5013; Pomirchy M et al., Lancet Neurology (2026), doi:10.1016/S1474-4422(25)00455-7.
Newer vaccine, bigger databases
For Shingrix, the vaccine people are actually offered now, there are no birth-date experiments, only observational studies. They are large. Maxime Taquet and colleagues at Oxford used the switch in US practice from Zostavax to Shingrix in October 2017 and compared 103,837 people who received each. Those given the newer vaccine lived 17% longer without a dementia diagnosis over six years, an average of 164 extra diagnosis-free days among those who developed dementia. The difference was larger in women (22%) than in men (13%). In June 2026, a study of 509,926 Medicare patients aged 66 and over who had stayed in a skilled nursing facility, funded by Shingrix’s maker GSK, reported that 18.8% of those vaccinated and 24.6% of those not vaccinated developed dementia within four years.

People who choose to be vaccinated tend to be healthier, better off and more engaged with their doctors than people who do not, which biases such comparisons. A Kaiser Permanente study published in February 2026 shows how much. Two doses of Shingrix, compared with no shingles vaccine, came with a hazard ratio for dementia of 0.49 (roughly half the risk). Compared with people who had received a tetanus-diphtheria-pertussis booster instead, another marker of a person who gets vaccinated, the hazard ratio was 0.73.
An Oxford follow-up found that both the shingles vaccine and an RSV vaccine that uses the same AS01 adjuvant were associated with lower dementia risk over 18 months, with no difference between them. That is consistent with the idea that the immune boost from the adjuvant, rather than protection against shingles, might matter. It is also consistent with both groups simply being healthier than average.
The same vaccine, two comparison groups
Hazard ratio for dementia after two doses of Shingrix, depending on whom the vaccinated are compared with. Lower means less dementia.
Source: Rayens EA et al., Nature Communications (2026), doi:10.1038/s41467-026-69289-0. Observational; the gap between the two figures reflects differences between people who do and do not get vaccinated.
Why the numbers may not hold
A pointed critique came in September 2026 from Mika Kivimäki and colleagues, including Gill Livingston of the Lancet dementia commission. They took each natural experiment and worked back to the effect it implied for a person who was actually vaccinated: 18% for Wales, 177% for Australia, and 84% and 111% for Canada’s two cutoffs. A vaccine cannot prevent more than 100% of cases, so at least two of these figures are impossible, and they cannot all be estimates of the same thing. The authors also pointed out that national dementia rates in the three countries have not fallen in the way such large effects would suggest.
Implied effect per vaccinated person
The reduction in dementia diagnoses implied by each natural experiment, worked back to people who were actually vaccinated, according to a 2026 critique.
Source: Kivimäki M, Frank P, Livingston G, Sipilä PN, Brain, Behavior, and Immunity (2026), doi:10.1016/j.bbi.2026.107021. Figures above 100% are not biologically possible, which is the critique’s point.
Under-recording of vaccination in Australian records would inflate the implied effect, and small denominators make such back-calculations unstable. The critique still lands on real weaknesses. The outcome in every study is a recorded diagnosis, which can be delayed or missed without the disease changing. The Oxford team saw hints that the advantage narrowed by year six, which fits a delay as well as a prevention. Effects concentrated in women are biologically possible but also a warning sign when they appear in some studies and not others. And the natural-experiment evidence concerns a vaccine that is being phased out.
The researchers behind the original work agree on the remedy. Geldsetzer, writing in Nature Medicine in June 2026, called for large randomised trials, and in May 2026 he told a neurology conference that one is “really needed.” No trial with dementia as its outcome has yet reported.
Who is offered the vaccine

Vaccination policy rests on preventing shingles, not dementia. In the United States, the CDC recommends two doses of Shingrix, two to six months apart, for adults aged 50 and over and for adults aged 19 and over with weakened immune systems. In the UK, Shingrix replaced Zostavax for the whole programme in September 2023, and until August 2028 it is offered to people turning 65 or 70; from September 2028 to people turning 60 or 65; and from September 2033 routinely at 60. People who are severely immunosuppressed are eligible from 18.
Trial participants reported a sore arm, tiredness and aches for a day or two more often than those on placebo, and these common side effects are the trade-off the eligibility rules are based on.
Eligibility today: the CDC and UK schedules side by side
This section reports who is currently offered the shingles vaccine on official pages. It is general information, not medical advice. None of the three official pages we read (CDC, GOV.UK, NHS) mentions dementia, so the vaccine is not recommended on those pages for that reason; the dementia question belongs to the studies discussed above.
| Where | Who | Doses |
|---|---|---|
| United States (CDC, reviewed Oct. 22, 2024) | Immunocompetent adults aged 50 and older; adults aged 19 and older who are or will be immunodeficient or immunosuppressed | Two doses 2–6 months apart; for immunocompromised people who would benefit from finishing sooner, the second dose can be given 1–2 months after the first. If more than 6 months have passed, give the second dose as soon as possible and do not restart. |
| United Kingdom (GOV.UK, updated Sept. 2, 2025) | Severely immunosuppressed people from age 18; immunocompetent people from age 60, phased in over 10 years starting with those turning 65 and 70 | Two doses at least 8 weeks apart; severely immunosuppressed 8 weeks to 6 months; immunocompetent 8 weeks to 12 months (NHS pages say 6 to 12 months apart for the age-based groups) |
The UK phase-in has dates. From Sept. 1, 2023 to Aug. 31, 2028 the programme covers people turning 70 and 65; from Sept. 1, 2028 to Aug. 31, 2033, those turning 65 and 60; from Sept. 1, 2033 everyone turning 60. People aged 70 to 79 who have not had the vaccine remain eligible up to their 80th birthday.
What we could not confirm: the NHS eligibility page was last reviewed in Sept. 2023 and its review date has passed, so use GOV.UK for programme dates; we did not fetch the CDC’s separate Shingrix recommendations page or the JCVI statement.
What the evidence supports
The natural experiments are among the cleverest pieces of evidence in dementia research, and their direction is consistent across three countries. Their sizes, though, do not fit together, as the critique shows. The Shingrix studies are large but cannot escape the fact that vaccinated people differ from unvaccinated ones. The fair summary is that a protective effect is plausible and worth a trial, though it is not established. The reason to be vaccinated remains the one the trials proved: fewer cases of shingles and of the nerve pain that can follow it.
What to do
Steps sorted by when they matter. Each one says how strong the evidence is: Measured Official advice Untested
Before
- Check whether you are eligible for the shingles vaccine. In the US, two doses of Shingrix are recommended from age 50; in the UK it is offered by birthday age. Official advice see Sources
- Expect a sore arm, tiredness and aches for a day or two. Official advice see Sources
What not to do
- Do not get it for dementia protection. That effect is plausible but not established; the proven reason is fewer cases of shingles and the nerve pain that can follow. Measured see Sources
Not medical advice. Ask your doctor or pharmacist about eligibility.
Questions people ask
Does the shingles vaccine prevent dementia?
It might reduce or delay dementia diagnoses, according to natural experiments and observational studies, but no randomised trial has tested it and the effect sizes are disputed.
Which vaccine was studied in Wales?
The live vaccine, Zostavax. Current programmes in the UK and US use the recombinant vaccine, Shingrix, for which the evidence on dementia is observational.
Why did the effect appear mainly in women?
Nobody knows. Differences in immune response are one proposed explanation, but the sex difference was not seen in the Australian study, which weakens confidence in it.
Who can get the shingles vaccine?
In the US, adults aged 50 and over, and younger adults with weakened immune systems. In the UK, eligibility depends on age and is moving towards 60.
How does shingles relate to dementia biologically?
That is still a hypothesis. Proposals include fewer viral reactivations, broader effects on the immune system and less inflammation in blood vessels of the brain.
The short version
- In Wales, people born just after a 1933 cutoff could get the shingles vaccine and those born just before could not. Over seven years, vaccination cut new dementia diagnoses by 3.5 percentage points, a 20% relative reduction.
- Similar natural experiments in Australia and Canada found smaller effects of eligibility, about 2 percentage points; the Welsh effect was concentrated in women.
- Studies of the newer Shingrix vaccine are observational. One found a hazard ratio of 0.49 against the unvaccinated but 0.73 against people who had a different vaccine, a sign of how much healthy-vaccinee bias can inflate results.
- A 2026 critique argued that the effects implied by the natural experiments are internally inconsistent, with two of them above 100%. No randomised trial has yet tested dementia as an outcome.
- The vaccine’s proven benefit is against shingles itself: Shingrix was 97.2% effective in adults aged 50 and over and 89.8% in those aged 70 and over.
This article summarises published research and public-health guidance for general information. It is not medical advice. Whether and when to be vaccinated depends on your age, health and local programme; ask your doctor, nurse or pharmacist.
Further reading: Eyting et al., Nature 641 (2025), for the Welsh natural experiment and its checks. Kivimäki et al., Brain, Behavior, and Immunity (2026), for the case that the results do not fit together. The CDC’s clinical overview of shingles for the baseline risks.
Sources
- Eyting M, Xie M, Michalik F, Heß S, Chung S, Geldsetzer P. Nature 641:438–446 (2025), doi:10.1038/s41586-025-08800-x.
- Pomirchy M et al. JAMA (2025), doi:10.1001/jama.2025.5013.
- Pomirchy M et al. Lancet Neurology (2026), doi:10.1016/S1474-4422(25)00455-7.
- Xie M, Eyting M, Bommer C, Ahmed H, Geldsetzer P. Cell (2025), doi:10.1016/j.cell.2025.11.007.
- Taquet M, Dercon Q, Todd JA, Harrison PJ. Nature Medicine (2024), doi:10.1038/s41591-024-03201-5.
- Taquet M, Todd JA, Harrison PJ. npj Vaccines (2025), doi:10.1038/s41541-025-01172-3.
- Rayens EA et al. Nature Communications (2026), doi:10.1038/s41467-026-69289-0.
- Annals of Internal Medicine (2026), doi:10.7326/ANNALS-25-04689.
- Kivimäki M, Frank P, Livingston G, Sipilä PN. Brain, Behavior, and Immunity (2026), doi:10.1016/j.bbi.2026.107021.
- Geldsetzer P. Nature Medicine (2026), doi:10.1038/s41591-026-04474-8.
- Lal H et al. NEJM (2015), doi:10.1056/NEJMoa1501184.
- Cunningham AL et al. NEJM (2016), doi:10.1056/NEJMoa1603800.
- Oxman MN et al. NEJM (2005), doi:10.1056/NEJMoa051016.
- Baxter R et al. American Journal of Epidemiology 187(1):161 (2018).
- CDC, Shingles clinical overview and vaccine recommendations (2024).
- UK Health Security Agency, Shingrix programme letter (4 July 2023); NHS, Shingles vaccine (2026).
- CDC. Shingles Vaccine Recommendations, reviewed Oct. 22, 2024. cdc.gov.
- GOV.UK. Shingles immunisation programme: information for healthcare practitioners, updated Sept. 2, 2025. gov.uk.
- NHS. Who can have the shingles vaccine, reviewed Sept. 1, 2023. nhs.uk.
